Latest posts tagged with #ctDNA on Bluesky
Register today for our upcoming webinar with Fenting Yan, MD, PhD and Jamie McKenzie, MD highlighting three of the twelve studies presented at the San Antonio Breast Cancer Symposium (SABCS).
Reserve your spot: https://ow.ly/tLe450YtAIR
#Natera #ctDNA
Join Krzysztof Misiukiewicz, MD and Michael Krainock, MD, PhD on a live webinar as they review and discuss the latest clinical data supporting the use of Signatera™ #ctDNA molecular residual disease (MRD) testing to support HNSCC patient care.
Register here: https://ow.ly/ftph50YsAmW
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRQxmX
@ASCO
#SocialListening #LucidQuest
Reserve your spot today for our upcoming webinar, From ASCO GU to real-world practice: Personalized tumor-informed ctDNA in bladder cancer management.
🧬Learn how leading clinicians are using #ctDNA to guide management decisions.
Register here: https://ow.ly/uTHs50Ys3hu
@vadimkoshkin.bsky.social
Don’t miss our upcoming event, Shaping the future of skin cancer: Tumor-informed ctDNA-guided intervention.
Register here: https://ow.ly/tPbL50YrR6N
#ctDNA #Natera
🩸 Liquid Biopsy - Feb 2026
• Pan-cancer analysis identifies 14,202 methylation regions for cancer detection
• Multi-omics integration boosts cancer detection sensitivity in PROMISE study
• M-PACT classifies pediatric CNS tumors from low-input cfDNA
pir.sh/32p17rmgwv
#LiquidBiopsy #ctDNA
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRF805
@ASCO
#SocialListening #LucidQuest
In 1 hour at #AGBT2026 ⏳
🕒 2:40–3:00 PM
📍 Plenary Ballroom (Floridian)
Join our Bronze 2 Sponsor Workshop:
Clinical Oncology Applications of ctDNA Sequencing
Yuxuan Wang (@Johns Hopkins)
A focused 20-minute session for liquid biopsy & clinical genomics.
#ctDNA #Oncology #Genomics
Dinámica del ctDNA luego de 3 a 4 sem de iniciar los ICI en pac con melanoma avanzado parece ser un buen candidato para predecir la respuesta general al tratamiento, el riesgo de progresión y la supervivencia a largo plazo #ctDNA #melanoma ascopubs.org/doi/full/10.... ascopubs.org/doi/full/10....
Circulating Tumor DNA (ctDNA) Status for Occult Nodal Metastasis in Patients With Clinical Stage II Esophageal Squamous Cell Carcinoma (ESCC). SMC PPV and YUSH PPV graphs, SMC ROC curve and YUSH ROC curve.
Preoperative circulating tumor DNA (#ctDNA) detection in early-stage esophageal squamous cell carcinoma was associated with nodal metastasis and poorer survival, supporting its use for risk stratification.
ja.ma/4s2uH8k
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TR4sCY
@ASCO
#SocialListening #LucidQuest
ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC.
🔗https://buff.ly/S2kBuFe
#GastricCancer #HER2 #ctDNA
🧪 Liquid Biopsy — Jan 2026
• Post-treatment ctDNA predicts recurrence across multiple cancers
• Baseline mutation status refines prognosis in advanced disease
• CTCs and EV-derived signals guide therapy response
pir.sh/A5kgYmGg4m
#LiquidBiopsy #ctDNA #PrecisionOncology #CancerDiagnostics
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQvxV7
@ASCO
#SocialListening #LucidQuest
ADN tumoral circulante en CA colon estadio III resecado usando una prueba libre de tejido define los grupos de mal pronóstico con una carga elevada, dMMR y mutaciones específicas #ctDNA #CRC ascopubs.org/doi/abs/10.1...
Early NSCLC is entering a new era. Broad NGS profiling now identifies actionable mutations that guide adjuvant EGFR/ALK‑targeted therapy, influence immunotherapy decisions, and support ctDNA‑based MRD monitoring.
🔗 buff.ly/FKnT16B
#NSCLC #LungCancer #NGS #ctDNA #MRD #PrecisionOncology
🎙️ New Podcast Episode Alert!
In Episode 6 of Oncology Insights, Drs. Petros Grivas and Heather Parsons from @fredhutch.org dive into innovations in #BreastCancer care, including how circulating tumor DNA (#ctDNA) is reshaping detection and treatment decisions.
🎧 https://bit.ly/4aaD5Lz
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQkJJF
@ASCO
#SocialListening #LucidQuest
🔷 Postoperative ctDNA positivity and higher tumor fraction, were independently associated with worse disease free survival (DFS), time to recurrence, and overall survival (OS), supporting ctDNA-guided risk stratification.
🔗 Read more: bit.ly/ONCOnews02-F...
#ONCOnews #OncoAlert #OncEd #ctDNA
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQYRN4
@ASCO
#SocialListening #LucidQuest
Hoping #ctDNA can help sort this quickly in days to come. A simple blood test 2C who has #MBC #recurrence & who is all clear. Eliminates undue stress 4 many - and stress awakens dormant #DTCs per #SABCS25 data! + it gets early metsters into treatment ASAP so they have a chance.
#cansky #bcsm
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQPfK2
@ASCO
#SocialListening #LucidQuest
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQFj65
@ASCO
#SocialListening #LucidQuest
Development of a multimodal model integrating #ctDNA dynamics, normalized #bTMB, and first #RECIST response to predict durable benefit in #NSCLC patients treated with #ICIs, demonstrating high accuracy and robust validation.
#CoverPage in #STTT: doi.org/10.1038/s413...
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQ6Y9Q
@ASCO
#SocialListening #LucidQuest
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQ1J0W
@ASCO
#SocialListening #LucidQuest
6️⃣To support broader adoption of #ctDNA in #DLBCL, we have made our end-to-end pipeline AULE (Automated Ultrasensitive Lymphoma Evaluation) pipeline fully open-source on GitHub: github.com/Hodson-Bioin... #DIRECT
4️⃣One of the most important takeaways from #DIRECT is that the Limit of Detection (LoD) is not an "one-size-fits-all" figure. It is patient rather than assay specific. We found that this limit varied by more than two orders of magnitude across different patients. #DLBCL #ctDNA
